New York biopharma, Hoth Therapeutics, is forming a joint venture with Voltron Therapeutics to develop a self-assembling vaccine for the potential prevention of Covid-19.
The joint venture – dubbed HaloVax – will commence preclinical studies for the development of vaccine prospects to prevent Covid-19 based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
Supported by MGH, the two companies will work jointly on exploring and developing this SAV technology as a means to aid patients at risk of being infected with Covid-19.
The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets.
The technology which received Department of Defense (DoD) funding has demonstrated proof of concept in Lassa Fever, an emerging infectious disease.
HaloVax intends to use these same SAV principles to assist in the development of a potential vaccine against the Covid-19 pandemic.
Hoth believes VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy.
In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.
Pursuant to the agreement, Hoth shall be granted the right to receive single digit royalties from the sale of any products developed, and shall have the right to acquire up to a 30% equity interest in HaloVax.